FDA News

Latest News

Benralizumab Receives FDA Approval as Add-On Maintenance Therapy for Asthma
Benralizumab Receives FDA Approval as Add-On Maintenance Therapy for Asthma

April 11th 2024

The FDA approval of benralizumab for patients ages 6 to 11 with asthma follows the conclusions of the phase 3 TATE study.

Product image of Resmetirom (Rezdiffra) | Credit: Madrigal Pharmaceuticals
Resmetirom (Rezdiffra) Now Available in US Pharmacies, Marks Turning Point in NASH Management

April 9th 2024

FDA Acceptance Announced of sBLA for Bimekizumab HS Treatment, 2mL Administration Devices
FDA Acceptance Announced of sBLA for Bimekizumab HS Treatment, 2mL Administration Devices

April 4th 2024

FDA Approves TriClip TEER System for Tricuspid Regurgitation
FDA Approves TriClip TEER System for Tricuspid Regurgitation

April 2nd 2024

The FDA Approves Iloperidone for Bipolar I Disorder
FDA Approves Iloperidone (Fanapt) for Acute Treatment of Bipolar I Disorder

April 2nd 2024

More News

© 2024 MJH Life Sciences

All rights reserved.